Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has scheduled a webinar for Tuesday, September 2, 2025, at 8:00 a.m. ET to announce their lead in vivo development candidate. The presentation will be accessible through a webcast link and the company's investor relations website.

The webinar will focus on revealing details about their latest advancement in gene editing technology aimed at developing transformative medicines for serious diseases. A replay will be available in the Investors section of the Editas Medicine website following the presentation.

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.

Webinar Presentation Details:
The live and archived webcast of the Company’s webinar presentation will be accessible through this webcast link, or through the Events & Presentations page of the “Investors” section of the Company’s website.

A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

About Editas Medicine 
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

Investor and Media Contacts: 
ir@editasmed.com 
media@editasmed.com

FAQ

When is Editas Medicine (EDIT) hosting its webinar to announce the lead in vivo development candidate?

Editas Medicine will host the webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET.

How can investors access Editas Medicine's (EDIT) September 2025 webinar presentation?

Investors can access the webinar through a dedicated webcast link or through the Events & Presentations page in the Investors section of Editas Medicine's website.

Will there be a replay available of Editas Medicine's (EDIT) September 2025 development candidate announcement?

Yes, a replay of the webinar will be available in the Investors section of the Editas Medicine website at www.editasmedicine.com upon conclusion of the presentation.

What will Editas Medicine (EDIT) announce during their September 2025 webinar?

Editas Medicine will announce the selection of their lead in vivo development candidate for their gene editing program focused on serious diseases.